NEW YORK , Aug. 13, 2024 /PRNewswire/ -- The global immunodiagnostics market size is estimated to grow by USD 29.54 billion from 2024-2028, according to Technavio.
The market is estimated to grow at a CAGR of almost 13.64% during the forecast period. Increased demand for biomarker-based tests is driving market growth, with a trend towards growth in demand for personalized medicine.
However, complexity of immunodiagnostics tests poses a challenge. Key market players include Abbott Laboratories, Adaptive Biotechnologies Corp., AESKU.
GROUP GmbH and Co. KG, bioMerieux SA, Danaher Corp., DiaSorin SpA, Exagen Inc.
, F. Hoffmann La Roche Ltd., HUMAN Gesellschaft fur Biochemica und Diagnostica mbH, Nexus Dx Inc.
, Omega Diagnostics Group Plc, OraSure Technologies Inc., QuidelOrtho Corp., Seramun Diagnostica GmbH, Siemens AG, SQI Diagnostics Inc.
, Sysmex Corp., Tecan Trading AG, Thermo Fisher Scientific Inc., and Werfenlife SA.
Get a detailed analysis on regions, market segments, customer landscape, and companies- View the snapshot of this report Immunodiagnostics Market Scope Report Coverage Details Base year 2023 Historic period 2018 - 2022 Forecast period 2024-2028 Growth momentum & CAGR Accelerate at a CAGR of 13.64% Market growth 2024-2028 USD 29545.4 million Market structure Fragmented YoY growth 2022-2023 (%) 11.
73 Regional analysis North America, Europe, Asia, and Rest of World (ROW) Performing market contribution Europe at 37% Key countries US, UK, Germany, Canada, and China Key companies profiled Abbott Laboratories, Adaptive Biotechnologies Corp., AESKU.GROUP GmbH and Co.
KG, bioMerieux SA, Danaher Corp., DiaSorin SpA, Exagen Inc., F.
Hoffmann La Roche Ltd., HUMAN Gesellschaft fur Biochemica und Diagnostica mbH, Nexus Dx Inc., Omega Diagnostics Group Plc, OraSure Technologies Inc.
, QuidelOrtho Corp., Seramun Diagnostica GmbH, Siemens AG, SQI Diagnostics Inc., Sysmex Corp.
, Tecan Trading AG, Thermo Fisher Scientific Inc., and Werfenlife SA Market Driver The trend towards personalized medicine is driving a significant demand for precise diagnostic tools. Immunodiagnostics plays a crucial role in this field by enabling accurate identification of disease biomarkers at the molecular level.
With personalized medicine, treatments are tailored to individual patients based on factors such as age, gender, and disease severity. This approach requires highly sensitive and specific diagnostic tests. Immunodiagnostics delivers this capability, making it a vital component of precision medicine.
Its ability to identify specific targets for diseases like cancer and autoimmune conditions helps clinicians select the most effective treatments for their patients. As personalized medicine gains popularity, the global immunodiagnostics market is poised for growth. Immunodiagnostics is a significant segment of the in vitro diagnostics market, focusing on the detection of various diseases using immunological reactions.
Trends include infectious diseases such as HIV, Hepatitis B, Dengue, and Sexually Transmitted Infections (STIs), as well as cardiovascular diseases, cancer, gastrointestinal diseases, and chronic conditions. The geriatric population's demographics and lifestyle factors contribute to the market's growth. Diagnosis kits and analyzers are essential tools, with immunoassay techniques like antigen-antibody reactions and chemiluminescence immunoassay (CLIA) leading the way.
Biomarker discovery and stringent regulatory requirements are key areas of focus. Technological advancements address technical limitations and false results, while healthcare expenditure and regulatory scenarios influence pricing analysis. Autoimmune disorders, endocrinology, oncology, and pathologists in hospitals and clinics utilize these tests for accurate diagnosis.
Discover 360° analysis of this market. For complete information, schedule your consultation - Book Here! Market Challenges For more insights on driver and challenges - Request a sample report! Segment Overview This immunodiagnostics market report extensively covers market segmentation by 1.1 Reagents and consumables - The reagents and consumables segment in the immunodiagnostics market is projected to expand significantly compared to the immunodiagnostic instruments market.
The increasing demand for high-throughput screening using immunoassays has resulted in the production of new reagents for antigen detection. Technological advancements, such as fluorescence and chemiluminescence, have been integrated with new reagents, driving market growth. Companies are expanding their product portfolios to cater to the growing number of immunodiagnostic tests available.
Roche Diagnostics is an example of a company specializing in reagents for oncology testing. Strategic partnerships between manufacturers and insurers with hospitals or other end-users are also increasing reagent sales, contributing to market expansion. Despite heterogeneous reimbursement scenarios, this trend is expected to continue throughout the forecast period.
For more information on market segmentation with geographical analysis including forecast (2024-2028) and historic data (2017-2021) - Download a Sample Report Learn and explore more about Technavio's in-depth research reports The global Helicobacter pylori diagnostics market is projected to grow significantly, driven by increasing awareness and advancements in diagnostic technologies. This market encompasses a range of diagnostic tools, including breath tests, stool antigen tests, and serology assays, designed to detect H. pylori infection, a common cause of peptic ulcers and gastric cancer.
The rise in prevalence of gastrointestinal disorders and the growing demand for non-invasive testing methods are key factors fueling market expansion. Major players are focusing on innovative solutions to enhance accuracy and patient comfort in diagnosis. Research Analysis Immunodiagnostics is a vital segment of in vitro diagnostics, focusing on the detection of various diseases using immunological reactions.
This market encompasses a broad spectrum of applications, including infectious diseases such as HIV, Hepatitis B, STI, and Autoimmunity diseases. Additionally, it plays a significant role in diagnosing chronic conditions like cardiovascular diseases, cancer, gastrointestinal diseases, and chronic diseases. The aging population and associated demographic shifts, along with lifestyle changes, have fueled the demand for immunodiagnostics.
Market Research Overview Immunodiagnostics is a critical area of in-vitro diagnostics, focusing on the detection and quantification of antigen-antibody reactions to identify various diseases. The market encompasses infectious diseases such as HIV, Hepatitis B, Dengue, Chikungunya, STI, and autoimmune disorders like Rheumatoid arthritis and Systemic Lupus Erythematosus. Demographics, lifestyle, and governing scenarios influence the immunodiagnostics market, particularly the growing geriatric population and the rise in chronic diseases.
Technological advancements in immunodiagnostics include chemiluminescence immunoassay (CLIA), enzyme-linked immunosorbent assay (ELISA), and flow cytometry. Table of Contents: 1 Executive Summary 2 Market Landscape 3 Market Sizing 4 Historic Market Size 5 Five Forces Analysis 6 Market Segmentation 7 Customer Landscape 8 Geographic Landscape 9 Drivers, Challenges, and Trends 10 Company Landscape 11 Company Analysis 12 Appendix About Technavio Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contacts Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: www.technavio.
com/ View original content to download multimedia: https://www.prnewswire.com/news-releases/immunodiagnostics-market-size-is-set-to-grow-by-usd-29-54-billion-from-2024-2028--increased-demand-for-biomarker-based-tests-boost-the-market-technavio-302220026.
html SOURCE Technavio.
